Forendo Pharma Oy announced to have closed its first investment round with the leading Nordic start-up investors Karolinska Development AB, Novo Seeds and Finnvera. The tranched funding commitments together with funding from Finnish Tekes will reach 10 million euros.
Forendo Pharma is a newly established drug development company based in Turku, Finland. Its core competence resides in organ specific hormone mechanisms, giving new opportunities to unmet needs in women s and men s health. Forendo Pharma has acquired from Hormos Medical the drug development programs for endometriosis and male low testosterone.
Read more: www.turkusciencepark.com
